The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells

American Journal of Pathology

Volumn 168, Issue 5, 2006, Pages 1642-1653

  Engström, Katarina ^a   Willén, Helena ^b   Kåbjörn Gustafsson, Christina ^a   Andersson, Carola ^a   Olsson, Marita ^c   Göransson, Melker ^a   Järnum, Sofia ^a   Olofsson, Anita ^a   Warnhammar, Elisabeth ^a   Åman, Pierre ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DNA BINDING PROTEIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; LEUCINE ZIPPER PROTEIN; RNA; RNA BINDING PROTEIN; TRANSCRIPTION FACTOR;

ADIPOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL TYPE; FIBROSARCOMA; FLUORESCENCE MICROSCOPY; FUSION GENE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIPOSARCOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; ONCOGENE FUS DDIT3; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMA CELL; SCID MOUSE; TUMOR GROWTH; VASCULARIZATION; WESTERN BLOTTING;

EID: 33646535436     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2006.050872     Document Type: Article

References (38)

1. Fletcher CDM, Unni KK, Mertens F: Tumors of Soft Tissue and Bone. Lyon, France, IARC Press, 2000
2. Åman P, Ron D, Mandahl N, Fioretos T, Heim S, Arheden K, Willen H, Rydholm A, Mitelman F: Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11). Genes Chromosomes Cancer 1992, 5:278-285
3. Antonescu CR, Elahi A, Humphrey M, Lui MY, Healey JH, Brennan MF, Woodruff JM, Jhanwar SC, Ladanyi M: Specificity of TLS-CHOP rearrangement for classic myxoid/round cell liposarcoma: absence in predominantly myxoid well-differentiated liposarcomas. J Mol Diagn 2000, 2:132-138
4. Panagopoulos I, Åman P, Mandahl N, Mitelman F: Two distinct FUS breakpoint clusters in myxoid liposarcoma and acute myeloid leukemia with the translocations t(12;16) and t(16;21). Oncogene 1995, 11:1133-1137
5. Crozat A, Åman P, Mandahl N, Ron D: Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature 1993, 363:640-644
6. Rabbirts TH, Forster A, Larson R, Nathan P: Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nat Genet 1993, 4:175-180
7. Sanchez-Garcia I, Rabbitts TH: Transcriptional activation by TAL1 and FUS-CHOP proteins expressed in acute malignancies as a result of chromosomal abnormalities. Proc Natl Acad Sci USA 1994, 91:7869-7873
8. Åman P: Fusion genes in solid tumors. Semin Cancer Biol 1999, 9:303-318
9. Barr FG: Translocations, cancer and the puzzle of specificity. Nat Genet 1998, 19:121-124
10. Åman P: Fusion oncogenes in tumor development. Semin Cancer Biol 2005, 15:236-243
11. Åman P: Fusion oncogenes. Semin Cancer Biol 2005, 15:159-161
12. Panagopoulos I, Mandahl N, Ron D, Hoglund M, Nilbert M, Mertens F, Mitelman F, Aman P: Characterization of the CHOP breakpoints and fusion transcripts in myxoid liposarcomas with the 12; 16 translocation. Cancer Res 1994, 54:6500-6503
13. Thelin-Järnum S, Göranssson M, Schweizer-Burguete A, Olofsson A, Åman P: The Myxoid liposarcoma specific TLS-CHOP fusion protein localizes to nuclear structures distinct from PML nuclear bodies, Int J Cancer 2002, 97:446-450
14. Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J, Speed TP: Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 2002, 30:15
15. Cleveland WS, Devlin SJ: Locally weighted regression: an approach to regression analysis by local fitting, J Am Stat Assoc 1988, 83:596-610
16. Stålberg A, Zoric N, Åman P, Kubista M: Quantitative real-time PCR for cancer detection: the lymphoma case. Expert Rev Mol Diagn 2005, 5:221-230
17. Fletcher CDM, Unni KK, Mertens F: Pathology and Genetics of Tumors of Soft Tissue and Bone. Lyon, France, IARC Press, 2002
18. Kovar H: Context matters: the hen or egg problem in Ewing's sarcoma. Semin Cancer Biol 2005, 15:189-196
19. Zinszner H, Albalat R, Ron D: A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP. Genes Dev 1994, 8:2513-2526
20. Kuroda M, Ishida T, Takanashi M, Satoh M, Machinami R, Watanabe T: Oncogenic transformation and inhibition of adipocytic conversion of preadipocytes by TLS/FUS-CHOP type II chimeric protein. Am J Pathol 1997, 151:735-744
21. Perez-Losada J, Pintado B, Gutierrez-Adan A, Flores T, Banares-Gonzalez B, del Campo JC, Martin-Martin JF, Battaner E, Sanchez-Garcia I: The chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic mice. Oncogene 2000, 19:2413-2422
22. Barone MV, Crozat A, Tabaee A, Philipson L, Ron D: CHOP (GADD153) and its oncogenic variant, TLS-CHOP, have opposing effects on the induction of G1/S arrest. Genes Dev 1994, 8:453-464
23. Ron D: TLS-CHOP and the role of RNA-binding proteins in oncogenic transformation. Curr Top Microbiol Immunol 1997, 220:131-142
24. Tontonoz P, Singer S, Forman B, Sarraf P, Fletcher J, Fletcher C, Brun R, Mueller E, Altiok S, Oppenheim H, Evans R, Spiegelman B: Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid kappa receptor. Proc Natl Acad Sci USA 1997, 94:237-241
25. Teitell MA, Thompson AD, Sorensen PH, Shimada H, Triche TJ, Denny CT: EWS/ETS fusion genes induce epithelial and neuroectodermal differentiation in NIH 3T3 fibroblasts, Lab Invest 1999, 79:1535-1543
26. Rorie CJ, Thomas VD, Chen P, Pierce HH, O'Bryan JP, Weissman BE: The Ews/Fli-1 fusion gene switches the differentiation program of neuroblastomas to Ewing sarcoma/peripheral primitive neuroectodermal tumors. Cancer Res 2004, 64:1266-1277
27. Hu-Lieskovan S, Zhang J, Wu L, Shimada H, Schofield DE, Triche TJ: EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumors. Cancer Res 2005, 65:4633-4644
28. Perez-Mancera PA, Sanchez-Garcia I: Understanding mesenchymal cancer: the liposarcoma-associated FUS-DDIT3 fusion gene as a model. Semin Cancer Biol 2005, 15:206-214
29. Rous P, Murphy JB: On the causation by filterable agents of three distinct chicken tumors, J Exp Med 1914, 19:52-68
30. Shi X, Shi W, Li Q, Song B, Wan M, Bai S, Cao X: A glucocorticoid-induced leucine-zipper protein, GILZ, inhibits adipogenesis of mesenchymal cells. EMBO Rep 2003, 4:374-380
31. Perez-Losada J, Sanchez-Martin M, Rodriguez-Garcia MA, Perez-Mancera PA, Pintado B, Flores T, Battaner E, Sanchez-Garcia I: Liposarcoma initiated by FUS/TLS-CHOP: the FUS/TLS domain plays a critical role in the pathogenesis of liposarcoma. Oncogene 2000, 19:6015-6022
32. Jousse C, Bruhat A, Carraro V, Urano F, Ferrara M, Ron D, Fafournoux P: Inhibition of CHOP translation by a peptide encoded by an open reading frame localized in the chop 5′UTR. Nucleic Acids Res 2001, 29:4341-4351
33. Motro B, Itin A, Sachs L, Keshet E: Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci USA 1990, 87:3092-3096
34. Göransson M, Elias E, Stålberg A, Olofsson A, Andersson C, Åman P: Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression. Int J Cancer 2005, 1:1
35. Kuroda M, Wang X, Sok J, Yin Y, Chung P, Giannotti JW, Jacobs KA, Fitz LJ, Murtha-Riel P, Turner KJ, Ron D: Induction of a secreted protein by the myxoid liposarcoma oncogene. Proc Natl Acad Sci USA 1999, 96:5025-5030
36. Wilczynska M, Lobov S, Ohlsson PI, Ny T: A redox-sensitive loop regulates plasminogen activator inhibitor type 2 (PAI-2) polymerization. EMBO J 2003, 22:1753-1761
37. Darnell GA, Antalis TM, Johnstone RW, Stringer BW, Ogbourne SM, Harrich D, Suhrbier A: Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motif. Mol Cell Biol 2003, 23:6520-6532
38. Deneen B, Denny CT: Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/FLI1 mediated transformation. Oncogene 2001, 20:6731-6741